Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
Anaemia is a common consequence of chronic renal failure. Darbepoetin alfa is a unique
erythropoietic protein that stimulates erythropoiesis by the same mechanism as endogenous
erythropietin and conventional recombinant human erythropoietin (rHuEPO). Darbepoetin alfa
has been shown to have a serum half-life 3-fold longer than that of rHuEPO, which allows
dosing at extended intervals and less frequent injection.
The objective is to evaluate the efficacy and safety of darbepoetin alfa therapy given at an
extended once monthly dosing interval in the treatment of renal anaemia in continuous
ambulatory peritoneal dialysis.